Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-116-1 | CAS number: 7440-06-4
Endpoint summary
Administrative data
Description of key information
No relevant repeated dose toxicity data were identified.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
No data identified.
Additional information
No relevant human or laboratory animal repeated dose toxicity data were identified. However, availability considerations provide good support for the conclusion that a repeated dose toxicity study can be waived.
Platinum is considered to be non-bioavailable following oral and dermal exposure, as evidenced by transformation/dissolution and bio-elution test data.
It is not expected to reach the lungs in appreciable quantities (based on respiratory tract deposition modelling data). Thus, inhalation will not be a significant route of exposure. Further, bio-elution test data indicates lack of bioavailability in lung fluid.
Since a chemical is required to be bioavailable in order to induce systemic toxicity following repeated exposure, platinum is not considered to pose a systemic toxicity hazard. Finally, for animal welfare reasons, conducting new in vivo toxicity tests is considered as a last resort. Consequently, no testing for repeated dose toxicity of platinum is considered justified.
Justification for classification or non-classification
No repeated dose toxicity data are available for platinum. However, such effects are not expected, based on a lack of bioavailability following exposure via the oral, dermal and inhalation routes. As such, there is no evidence to classify it as STOT-RE according to EU CLP criteria (EC 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
